Ketogenic Diet for Pancreatic Cancer
Trial Summary
What is the purpose of this trial?
This study will evaluate the effects of the ketogenic diet in patients with metastatic pancreatic cancer while receiving chemotherapy.
Research Team
Steve Norton, MBA PhD
Principal Investigator
Translational Drug Development
Eligibility Criteria
This trial is for adults with metastatic pancreatic ductal adenocarcinoma who haven't been treated for their advanced disease. They must be able to perform daily activities (KPS ≥ 70%), have a life expectancy of at least 12 weeks, and measurable tumor lesions. Participants need a smartphone or computer, acceptable blood counts and organ function, and agree to use contraception if necessary. Excluded are those with severe malnutrition, certain heart conditions, recent major surgery, uncontrolled illnesses or infections.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either a ketogenic or non-ketogenic diet along with triplet chemotherapy (nab-paclitaxel, cisplatin, gemcitabine) administered intravenously on Days 1 and 8 every 21 days
Follow-up
Participants are monitored for progression-free survival, changes in serum metabolites, quality of life, and other secondary outcomes
Treatment Details
Interventions
- Ketogenic Diet
Find a Clinic Near You
Who Is Running the Clinical Trial?
Translational Drug Development
Lead Sponsor
Translational Genomics Research Institute
Collaborator